Actionable news
0
All posts from Actionable news
Actionable news in ABBV: ABBVIE Inc,

AbbVie's pan-genotypic HCV regimen ABT-493/ABT-530 achieves cure rates as high as 100% in 12 weeks in mid-stage studies

New data from two Phase 2 trials, SURVEYOR-1 and SURVEYOR-2, show AbbVie's (NYSE:ABBV) investigational regimen for the treatment of chronic hepatitis C virus (HCV) infection genotypes 1-6, ABT-493 and ABT-530, delivered cure rates (SVR12) as high as 100% after 12 weeks of treatment. The data were presented at The International Liver...


More